While inhalers are essential treatments for managing COPD and asthma, they contribute to CO2-equivalent emissions (CO2eq). However, switching from metered-dose inhalers (MDIs), which use hydrofluoroalkane (HFA) propellants, to dry powder inhalers (DPIs) in certain patient groups can substantially reduce healthcare-related CO2eq, according to a study published in BMJ Open Respiratory Research.
Advertisement
A literature review showed a significant increase in hyperkalemia among patients with CKD despite treatment with RAASi.
HER2DX predicts outcomes in early HER2+ breast cancer, adding prognostic value beyond standard clinical-pathologic factors.
CMV colitis complicates IBD flares, making diagnosis and treatment difficult; timely detection is key to better outcomes.
Researchers also measured in the study cohort a very high discontinuation rate for this agent.
Universal hepatitis C screening in EDs detects 34% more cases than risk-based testing but follow-up care remains low.
Mole count and genetics strongly impact mole-linked melanoma risk, while sun exposure affects both melanoma types equally.
Stopping antidepressants causes mild, short-term symptoms like dizziness but no early increase in depression.
Telehealth cuts COPD hospitalizations, improves quality of life, but shows no impact on oxygen therapy adherence.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
Researchers also measured in the study cohort a very high discontinuation rate for this agent.
In a cohort of adults and adolescents marstacimab produced bleed control superior to that from on-demand bypassing agent.
The agent notably in preclinical studies has accomplished increased HbF without any evident cytotoxicity.
The phase 3 VERONA trial, which compared this combination with placebo plus azacitidine, observed no new safety signals.
Dr. John Gansner and Dr. Martina H. Slingsby argue this new agent can provide benefit across all bleeding disorders.
Heme Today spoke with Ulrike Reiss, MD, and Andrew Davidoff, MD, of the trial's investigator team.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.